Amylyx reveals data from Phase III LUCIDITY trial of avexitide
Amylyx Pharmaceuticals has reported that its investigational GLP-1 receptor antagonist, avexitide, met its prespecified primary endpoint in the Phase III LUCIDITY trial for PBH.
The post Amylyx reveals data from Phase III LUCIDITY trial of avexitide appeared first on Clinical Trials Arena .